August 7, 2019 Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D.
August 5, 2019 Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
July 16, 2019 Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform
June 4, 2019 Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
April 15, 2019 Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
January 28, 2019 Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
January 8, 2019 UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
January 3, 2019 UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
December 4, 2018 Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
November 28, 2018 Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities
October 15, 2018 Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 27, 2018 Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors
September 14, 2018 Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
August 28, 2018 Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality
June 5, 2018 UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
